One of things we always have prided ourselves in at Centeno-Schultz Clinic is not overselling what we do. We constantly tell patients that stem cells (or PRP or other cellular therapies) are not Pixie dust, they are clinical tools that have a success rate and failure rate like any other tools we use everyday in clinical practice. For our cultured Regenexx procedure, we have meticously kept outcome and complications data and have published that data in the peer reviewed literature. In fact, we’re still publishing it (just this week we are both preparing our knee/hip outcome data for publication and revising an complications paper (n=339) for resubmission after a provisional journal acceptance). Rather than cherry picking our best successes and ignoring our failures, we constantly report both side of the coin by reporting publically all of our outcome data (the rock star patients with the patients that didn’t respond). So how is Regenexx-SD stacking up to the cultured cell procedure? Well, I’m happy to say that early returns look promising. About 1/2 of the patients are reporting 50% or greater improvement after a single same day injection of their own stem cells (with most Regenexx cultured patients we routinely injected the area three times). While this is only about 2 months of outcome data and some patients will likely still yet respond, it’s a good sign that we have created a same day stem cell procedure without some of the downsides of other centrifuge based cell therapies on the market.
(Data collected based on responses from patients to Likert Scale question of +100% improved to -100% worsened. Includes patients with severe ankle, hip, knee, and thumb osteoarthritis, most are total joint replacement candidates.)